Kymera Therapeutics (KYMR)
(Delayed Data from NSDQ)
$32.49 USD
-1.04 (-3.10%)
Updated May 29, 2024 04:00 PM ET
After-Market: $32.47 -0.02 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KYMR 32.49 -1.04(-3.10%)
Will KYMR be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for KYMR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KYMR
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
KYMR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
Wall Street Analysts Predict a 34.41% Upside in Kymera Therapeutics (KYMR): Here's What You Should Know
Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Other News for KYMR
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
Demystifying Kymera Therapeutics: Insights From 5 Analyst Reviews
Truist Financial Issues a Buy Rating on Kymera Therapeutics (KYMR)
Buy Rating for Kymera Therapeutics on Promising Early Data of KT-253 Drug Candidate
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting